Publications by authors named "Maria Del Mar Freijo Guerrero"
Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial).
Trials
January 2024
Rationale: In-stent reocclusion after endovascular therapy has a negative impact on outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Optimal antiplatelet therapy approach in these patients to avoid in-stent reocclusion is yet to be elucidated.
Aims: To assess efficacy and safety of intravenous tirofiban versus intravenous aspirin in patients undergoing MT plus carotid stenting in the setting of AIS due to TL.
Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol.
Eur Stroke J
March 2023
Background: In-stent thrombosis after mechanical thrombectomy (MT) worsen outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Although an optimal antiplatelet therapy is needed, the best approach to avoid in-stent thrombosis is yet to be elucidated.
Hypothesis: Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL.
Article Synopsis
- Stroke is a leading cause of death and disability, with reperfusion therapies being the only acute treatment; however, recent trials suggest a longer time window for these therapies may increase severe complications like parenchymal hematoma (PH).
- The study aimed to identify genetic risk factors associated with PH in order to find potential preventive or treatment targets and explored genetic links to other conditions.
- A genome-wide association study (GWAS) identified a significant variant (rs79770152) and a suggestive one (rs13297983) related to PH, revealing genetic overlaps with Alzheimer's disease and other brain conditions.
Article Synopsis
- Intracerebral hemorrhage (ICH) rates are significantly higher in patients taking anticoagulants, and a study in Spain aims to analyze trends in ICH-OAC occurrences over time.
- The research combined data from three major studies (2008-2015), including over 600 patients, to assess changes in ICH-OAC incidence.
- Findings show a 3.73-fold increase in ICH-OAC cases, with aging populations being a contributing factor to the rising rates.
Symptomatic intracranial embolic foreign-body reactions after endovascular neurointerventional procedures: A retrospective study in a tertiary hospital.
Clin Neurol Neurosurg
January 2021
Introduction: Polymer-coats may peel-off the surface of catheters and devices during endovascular procedures and might lead to brain inflammatory foreign-body reactions.
Methods: We conducted a retrospective, descriptive, single-centre study including all patients with symptomatic intracranial oedematous and contrast-enhancing lesions after any neurointerventional procedure performed in our hospital between 2013 and 2019.
Results: From a total of 7446 neurointerventional procedures, 11 cases were identified (9 female, 2 male, median age 47 year-old), with an incidence of 0.
Epidemiology of Intracranial Hemorrhage Associated with Oral Anticoagulants in Spain: Trends in Anticoagulation Complications Registry - The TAC 2 Study.
Interv Neurol
April 2018
Objective: Patients receiving treatment with oral anticoagulants (OACs) are at risk of intracranial hemorrhage (ICH). In this study, we describe the epidemiological and clinical characteristics of patients receiving OACs who experience ICH and compare those receiving vitamin K antagonists (ICH-VKAs) with those receiving direct OACs (ICH-DOACs).
Methods: We performed a national, multicenter, descriptive, observational, retrospective study of all adult patients receiving OACs who were admitted to the neurology department with ICH over a 1-year period.
Epidemiology of Intracranial Haemorrhages Associated with Vitamin K Antagonist Oral Anticoagulants in Spain: TAC Registry.
Interv Neurol
October 2015
Background: Vitamin K antagonist oral anticoagulants (VKA-OACs) are effective for primary and secondary prevention of embolic events. The rate of haemorrhagic neurological complications in patients admitted to neurology departments in Spain is not yet known.
Aims: We aimed to determine the clinical and epidemiological characteristics of patients with intracranial haemorrhage secondary to VKA-OACs as well as the incidence of this severe complication.